Dynavax Techs

DVAX NASDAQ
4.330
+0.340
+8.52%
After Hours: 4.330 0 0.00% 16:59 08/19 EDT
Open
4.040
Prev Close
3.990
High
4.370
Low
4.040
Volume
2.11M
Avg Vol (3M)
1.74M
52 Week High
14.35
52 Week Low
2.595
% Turnover
3.23%
Market Cap
282.12M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Dynavax Techs DVAX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.
MORE >

Recently

Name
Price
%Change